AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Medication for adhd slow kid down3/21/2024 Each boy was asked to identify his stage of puberty using Tanner staging with the help of pictures. Height and weight measurements were taken at study enrolment, and a review of medical records was undertaken to obtain each boy’s baseline measurements (before starting treatment). The dose of medication was titrated to the lowest dose giving a satisfactory therapeutic response. Dexamphetamine was prescribed if the response to methylphenidate was suboptimal or as an alternative for boys with significant side effects. Methylphenidate was the drug of first choice for boys with ADHD. Parental informed consent was obtained, together with consent from all participating children. Ethics approval was granted by the Sydney West Area Health Service Human Research Ethics Committee. S C and P T invited an estimated 84% and 50% of their eligible patients to participate and recorded no refusals (estimated on the premise that children on long-term treatment are reviewed every 6 months). Over this period, A P invited all eligible boys to participate only two refused. A P recruited for the entire period S C and P T recruited from February to May 2006 and S C from March to July 2007. Having anthropometry at two time points for each child meant that growth velocities could also be compared.įor the ADHD group, adolescent boys aged 12.00–15.99 years with ADHD diagnosed according to Diagnostic and statistical manual of mental disorders, fourth edition, criteria and treated continuously with stimulant medication for at least 3 years, and who had pretreatment growth data available, were recruited from three paediatric practices in western Sydney between May 2005 and August 2011. To monitor growth and development in boys receiving stimulant treatment for ADHD, we used cross-sectional measures of anthropometry and pubertal stage in adolescence and of anthropometry in childhood, and compared these data with similar data from childhood and adolescence in boys without ADHD ( Box 1). To maintain adequate height velocity during puberty, we recommend keeping the dose as low as possible. The dose of medication was inversely correlated with the height velocity from baseline to 14.00–15.99 years of age ( P < 0.05).Ĭonclusions: Prolonged treatment (more than 3 years) with stimulant medication was associated with a slower rate of physical development during puberty. At 12.00–13.99 years of age, the subjects were comparable to the controls in their pubertal development adjusted for age, but those aged 14.00–15.99 years reported significant delay (mean Tanner stage, 3.6 for subjects v 4.0 for controls P < 0.05). Compared with the controls, after adjusting for current age and baseline growth parameter z score, subjects aged 12.00–13.99 years had significantly lower weight and body mass index ( P < 0.01), and those aged 14.00–15.99 years had significantly lower height and weight ( P < 0.05). At baseline, their growth parameters were not significantly different from those of the controls after adjusting for age. Results: Sixty-five subjects were recruited mean duration of treatment was 6.3 ± 1.9 years. The subjects’ pubertal staging and height velocity were related to their treatment history. Main outcome measures: Subjects’ growth parameters before treatment were compared with controls aged 7 or 8 years growth parameters and longitudinal changes on treatment to ages 12.00–13.99 and 14.00–15.99 years were compared with controls reviewed at 13 and 15 years of age, respectively. Objective: To investigate the growth and pubertal attainment of boys with attention deficit hyperactivity disorder (ADHD) on stimulant medication.ĭesign, setting and participants: Longitudinal study of boys aged 12.00–15.99 years at recruitment in 2005–2011, with stimulant-treated ADHD for at least 3 years, attending three paediatric practices (subjects), compared with longitudinal data from 174 boys from the Nepean longitudinal study (controls). Statistics, epidemiology and research design.
0 Comments
Read More
Leave a Reply. |